ScreenerHero

JAZZJazz Pharmaceuticals plc

NAS · US · Healthcare · Biotechnology · jazzpharma.com
254.28USDMkt Cap: 16.51B $P/E: 17.39

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (ED…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0
CORT
Corcept Therapeutics Incorporated
$13.22BUSDP/E 271.7

Key Statistics

Company
Market Cap16.51B $
Enterprise Value18.58B $
Revenue (TTM)4.60B $
Gross Profit3.76B $
Net Income (TTM)-356.15M $
Revenue/Share74.60 USD
Last Price254.28 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.9K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINIE00B4Q5ZN47
Valuation
P/E (Trailing)17.39
P/E (Forward)9.65
PEG0.96
EV/EBITDA9.64
EV/Revenue4.04
P/S3.51
P/B3.36
EPS (TTM)14.40
EPS (Forward)25.77
52W Range
248.7078% of range255.85
52W High255.85 USD
52W Low248.70 USD
Profitability
Gross Margin88.21%
Oper. Margin26.91%
EBITDA Margin41.88%
Profit Margin-8.35%
ROE-8.25%
ROA-3.05%
Growth
Revenue Growth15.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF1.36B $
CapEx (TTM)209.75M $
FCF Margin31.07%
FCF Yield8.66%
Net Debt2.21B $
Net Debt/EBITDA1.15
Balance Sheet
Debt/Equity1.26
Current Ratio1.78
Quick Ratio1.38
Book Value/Sh74.10 USD
Cash/Share33.89 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)281.35 USD
Upside (mean)+10.6%
Target Range196.00 USD – 315.00 USD
$196.00+10.6% to mean$315.00
# Analysts20
Ownership
Shares Out.64.91M
Float62.94M
Insiders2.99%
Institutions103.04%
Short Interest
Short Ratio4.7d
Short % Float5.32%
Short % Out.5.17%
Shares Short3.36M
Short (prev mo.)3.50M
Technical
SMA 50243.87 (+4.3%)
SMA 200198.91 (+27.8%)
Beta0.36
S&P 52W Chg21.00%
Avg Vol (30d)516.62K
Avg Vol (10d)703.51K
Technical Indicators
RSI (14)55.1
MACD1.2210
MACD Signal2.0179
MACD Hist.-0.7969
BB Upper263.08 USD
BB Middle253.42 USD
BB Lower243.76 USD
BB Width7.63%
ATR (14)7.221 USD
Vol Ratio (20d)0.66x